C-ANCA/proteinase 3-positive colitis in children: A distinctive form of inflammatory bowel disease or vasculitis with colitis as initial presentation?

Journal of Pediatric Gastroenterology and Nutrition

Volumn 57, Issue 4, 2013, Pages 489-492

  Van Biervliet, Stephanie ^a   Bonroy, Carolien ^b   Velde, Saskia Vande ^a   De Bruyne, Ruth ^a   Van Winckel, Myriam ^a   Peeters, Harald ^a   Delanghe, Joris ^b   Stove, Veronique ^b   De Vos, Martine ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Laboratory of Clinical Biology   (Belgium)

Author keywords

ANCA; Inflammatory bowel disease; Vasculitis

Indexed keywords

MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ANCA ASSOCIATED VASCULITIS; ARTICLE; BILIARY TRACT DISEASE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; INTESTINAL BLEEDING; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BILIARY TRACT DISEASES; CHILD; CHILD, PRESCHOOL; COLITIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MYELOBLASTIN; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 84885295723     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31829d4e9e     Document Type: Article

References (25)

1. Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol 2005; 19:263-76.
2. Tervaert JW, Huitema MG, Hene RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11.
3. Savige J, Dimech W, Fritzler M, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003;120:312-8.
4. Roozendaal C, Kallenberg CG. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin Exp Immunol 1999;116:206-13.
5. Roozendaal C, Van Milligen de Wit AW, Haagsma EB, et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med 1998;105:393-9.
6. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995;99: 49-56.
7. Sokol RJ, Farrell MK, McAdams AJ. An unusual presentation of Wegener's granulomatosis mimicking inflammatory bowel disease. Gastroenterology 1984;87:426-32.
8. Dimeo DE, Ferguson PJ, Bishop WP. An unusual intestinal presentation of C-ANCA/PR-3 positive vasculitis in a child. J Pediatr Gastroenterol Nutr 2005;40:368-70.
9. IBD Working Group of the European Society for Paediatric Gastroenterology Hepatology, and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1-7.
10. Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol 2010;105:2085-92.
11. Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009;15: 1218-23.
12. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
13. Lie JT. Wegener's granulomatosis: histological documentation of common and uncommon manifestations in 216 patients. Vasa 1997; 26:261-70.
14. Yi ES, Colby TV. Wegener's granulomatosis. Semin Diagn Pathol 2001;18:34-46.
15. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55:340-61.
16. Twilt M, Benseler S, Cabral D. Granulomatosis with polyangiitis in childhood. Curr Rheumatol Rep 2012;14:107-15.
17. Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"? Clin Rev Allergy Immunol 2009;36:40-51.
18. Taddei C, Audrain MA, Reumaux D, et al. Alpha1-antitrypsin phenotypes and anti-neutrophil cytoplasmic auto-antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:1293-8.
19. Elzouki AN, Eriksson S, Lofberg R, et al. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis 1999;5:246-52.
20. Xu J, Yang CH, Chen XY, et al. A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody. World J Gastroenterol 2008;14:7012-5.
21. Freeman HJ. Inflammatory bowel disease with cytoplasmic-staining antineutrophil cytoplasmic antibody and extensive colitis. Can J Gastroenterol 1998;12:279-82.
22. Freeman H. C-ANCA/PR-3 positive colitis may be a distinctive form of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005;41:135.
23. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995-1000.
24. Pollock W, Clarke K, Gallagher K, et al. Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate. J Clin Pathol 2002; 55:680-3.
25. Joossens S, Daperno M, Shums Z, et al. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem 2004;50:1422-5.